tbuckley/cabot-search huggingface dataset:
EP.06G.04 Clinicopathological Differences between EGFR Mutated and EGFR Wild-Type Lung Adenocarcinoma with Papillary Predominant Pattern
Authors: E. Goto, T. Taki, K. Nomura, T. Miyoshi, K. Tane, J. Samejima, K. Aokage, M. Nagamine, M. Kojima, S. Sakashita, N. Sakamoto, M. Tsuboi, G. Ishii
Journal: Journal of Thoracic Oncology (2024)
EP.08F.01 Predicting Radiation Pneumonitis with Baseline Pulmonary Function Tests in Patients with Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Authors: S.C. Tavolacci, X.A. Wang, G. Chun, J. Bloom, D.P. Mendoza, N. Tignor, T. Van Vleck, S. Chang, M. Chung, S. Tuminello, J. Wisnivesky, F.R. Hirsch, I. Cotarla, D. Simmons, K. Hsieh, R.M. Samstein, P. Wang, R. Veluswamy
Journal: Journal of Thoracic Oncology (2024)
EP.06D.05 The Prognostic Role of the Dynamic Changes in the Plasma ctDNA Levels in Advanced NSCLC after IO Initiation: A Meta-Analysis
Authors: G. Koronakis, N. Syrigos, M.S. Kamaratou, A. Koronaki, D. Grapsa, K. Thomopoulou, K. Syrigos
Journal: Journal of Thoracic Oncology (2024)
EP.08D.05 Long Term Follow-up of Two Decades Experience with Neoadyuvant Chemotherapy in Resectable Non Small Cell Lung Cancer
Authors: M. Antoñanzas, M. Amman, J.R. Jarabo, C. Aguado de la Rosa, E. Fernández, J-L. González-Larriba, C. Fraile, F. Hernando -Trancho
Journal: Journal of Thoracic Oncology (2024)
EP.06B.03 Performance of a Prognostic OTP, CD44, Ki-67 Biomarker Panel for Relapse in Paired Biopsies and Resections of Pulmonary Carcinoids
Authors: T. Van Weert, L. Moonen, L.M. Hillen, J. von der Thüsen, L. Lap, P. Group, R. Damhuis, A.-M. Dingemans, J. Derks, E.-J. Speel
Journal: Journal of Thoracic Oncology (2024)
EP.12B.06 Efficacy of Lorlatinib in Advanced ALK-Positive Non-Small Cell Lung Cancer Patients in Thailand: A Multicenter Study
Authors: K. Maneenil, T. Baisamut (Reungwetwattana), P. Sitthideatphaiboon, S. Payapwattanawong, K. Korphaisarn, T. Suksombooncharoen, C. Vinayanuwattikun
Journal: Journal of Thoracic Oncology (2024)
EP.05A.08 The Accuracy of Bronchoscopy and Transthoracic Needle Biopsy for Diagnosing Lung Cancer - A Systematic Review
Authors: E. Mascarenhas, C. Baldotto, A. GELATTI, T. VilasBoas Reis, M. Corassa, C.H. Andrade Teixeira, V.C. Cordeiro de Lima, G. Castro
Journal: Journal of Thoracic Oncology (2024)
Inducing disulfidptosis in tumors:potential pathways and significance
Authors: Tao Mi, Xiangpan Kong, Meiling Chen, Peng Guo, Dawei He
Journal: MedComm (2024)

Regulated cell death (RCD) is crucial for the elimination of abnormal cells. In recent years, strategies aimed at inducing RCD, particularly apoptosis, have become increasingly important in cancer therapy. However, the ability of tumor cells to evade apoptosis has led to treatment resistance and relapse, prompting extensive research into alternative death processes in cancer cells. A recent study identified a novel form of RCD known as disulfidptosis, which is linked to disulfide stress. Cancer cells import cystine from the extracellular environment via solute carrier family 7 member 11 (SLC7A11) and convert it to cysteine using nicotinamide adenine dinucleotide phosphate (NADPH). When NADPH is deficient or its utilization is impaired, cystine accumulates, leading to the formation of disulfide bonds in the actin cytoskeleton, triggering disulfidptosis. Disulfidptosis reveals a metabolic vulnerability in tumors, offering new insights into cancer therapy strategies. This review provides a detailed overview of the mechanisms underlying disulfidptosis, the current research progress, and limitations. It also highlights innovative strategies for inducing disulfidptosis and explores the potential of combining these approaches with traditional cancer therapies, particularly immunotherapy, to expedite clinical translation.
EP.05A.05 Brazilian Single-Center Experience in the Staging of Thoracic Neoplasms Using Endosonographic Methods (EUS/EBUS)
Authors: J.V.C. Assef, A. Gonçalves e Silva, P.C.B. Boscardim, S. de Lazari, G.F. Gomes, J. Mendes de Souza
Journal: Journal of Thoracic Oncology (2024)
EP.06B.15 Targetable Genetic Alterations Associated with Non-Small Cell Lung Cancer Mortality
Authors: H. Tupper, L.C. Sakoda, M.Z. Yang, R. Liu, V. Sarovar, N. Alcasid, H. Dong, W.T. Dyer, J. Yang, A.R. Patel, S.K. Ashiku, J.B. Velotta
Journal: Journal of Thoracic Oncology (2024)
EP.04A.17 Screening for Lung Cancer in Indonesia: Are All the Variables Valid for Determining These Factors?
Authors: E. Syahruddin, N.N. Soeroso, H. Haryati, S. Ermayanti, U.A. Setiawan, A.R. Setijadi, S. Sukarti, L. Wulandari, I.A. Jasminarti, M.A. Hanif, S.M. Munir
Journal: Journal of Thoracic Oncology (2024)
Targeting esophageal carcinoma: molecular mechanisms and clinical studies
Authors: Wenjing Wang, Lisha Ye, Huihui Li, Weimin Mao, Xiaoling Xu
Journal: MedComm (2024)

Abstract Esophageal cancer (EC) is identified as a predominant health threat worldwide, with its highest incidence and mortality rates reported in China. The complex molecular mechanisms underlying EC, coupled with the differential incidence of esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma (EAC) across various regions, highlight the necessity for in‐depth research targeting molecular pathogenesis and innovative treatment strategies. Despite recent progress in targeted therapy and immunotherapy, challenges such as drug resistance and the lack of effective biomarkers for patient selection persist, impeding the optimization of therapeutic outcomes. Our review delves into the molecular pathology of EC, emphasizing genetic and epigenetic alterations, aberrant signaling pathways, tumor microenvironment factors, and the mechanisms of metastasis and immune evasion. We further scrutinize the current landscape of targeted therapies, including the roles of EGFR, HER2, and VEGFR, alongside the transformative impact of ICIs. The discussion extends to evaluating combination therapies, spotlighting the synergy between targeted and immune‐mediated treatments, and introduces the burgeoning domain of antibody–drug conjugates, bispecific antibodies, and multitarget‐directed ligands. This review lies in its holistic synthesis of EC's molecular underpinnings and therapeutic interventions, fused with an outlook on future directions including overcoming resistance mechanisms, biomarker discovery, and the potential of novel drug formulations.
EP.11A.12 Real-World Treatment Patterns and Clinical Outcomes Following Chemotherapy and Anti-PD-(L)1 In Non-Small Cell Lung Cancer
Authors: V. Velcheti, J. Moore, H. Wang, X. Zhu, Y. Samyshkin, T. Ward, A. Christensen, C. Solem
Journal: Journal of Thoracic Oncology (2024)
EP.11C.02 Role of Immune-Related Adverse Events (irAEs) and Albumin in Non-Small-Cell Lung Cancer (NSCLC)
Authors: S. Bawek, S. Kalvapudi, Y. Vedire, A. Pachimatla, P. Jain, S. Yendamuri
Journal: Journal of Thoracic Oncology (2024)
EP.07F.08 Clinical Significance of Endothelial Programmed Cell Death Ligand 1 Expression in Patients with Non-Small Cell Lung Cancer
Authors: T. Saito, M. Ishida, N. Maru, T. Utsumi, H. Matsui, Y. Taniguchi, H. Hino, T. Murakawa
Journal: Journal of Thoracic Oncology (2024)
EP.12D.06 Real-World Cases on Efficacy and Safety of Savolitinib for Elderly Patients with NSCLC Harbouring METex14 Skipping Mutations
Authors: L. Li, Z. Zhang, Y. Xu, K. Xu, H. Wang, J. Li, T. Tian, H. Zhou, L. Xu, C. He, H. Tang, S. Wei
Journal: Journal of Thoracic Oncology (2024)
EP.13C.05 Factors Affecting Outcomes of Limited Stage (IIB-IIIC) Small Cell Lung Cancer: An Analysis of the National Cancer Database
Authors: H.M. Abdullah, A.C. Das, O.K. Abughanimeh, K.-L. Muir, B.B. Sharma, A.S. Marr, L.M. Smith, A.K. Ganti
Journal: Journal of Thoracic Oncology (2024)
EP.17A.04 Real-World Rates of Infusion-Related Reactions in Patients with EGFR-Mutant NSCLC Receiving Amivantamab
Authors: D.M. Gupta, C. Chang, L. Wendt, N. Mohindra, Y. Chae, D. Tobben, L.A. Gharzai, J.D. Patel
Journal: Journal of Thoracic Oncology (2024)
EP.06G.15 Rapid Immunohistochemistry of Microsatellite Instability Using Non-Contact Alternating Current Electric Field Mixing
Authors: K. Imai, H. Nanjo, Y. Wakamatsu, S. Takashima, T. Matsuo, S. Kuriyama, H. Suzuki, R. Demura, H. Iwai, S. Shibano, Y. Minamiya
Journal: Journal of Thoracic Oncology (2024)
EP.14C.09 Lung Metastasis of Clear Cell Renal Carsinoma Mimicking Primary Lung Cancer Following Nephectomy in 30 Years Old Women: A Case Report
Authors: P.G. Wahyu, A. Infianto, R.D. Wirawan Listiandoko, D. Wardani, D. Deschairul, H. Aprijadi, E.I. Pattiwael, M.R. Rahman
Journal: Journal of Thoracic Oncology (2024)
EP.12A.42 Savolitinib Plus Osimertinib in EGFR-Mutant NSCLC with MET Overexpression and Acquired Resistance to Previous EGFR Inhibitor
Authors: Y. Mao, Z. Huang, D. Cai, R. Lou, C. Shen, X. Wang, Y. Liu, X. Qi
Journal: Journal of Thoracic Oncology (2024)
EP.07A.16 The Prognostic Disparities Between the T3 Descriptors in Surgically Resected Primary Lung Cancer
Authors: A. Suzuki, M. Kawahara, Y. Yazaki, S. Yoshimine, J. Ichinose, Y. Matsuura, M. Nakao, S. Okumura, M. Mun
Journal: Journal of Thoracic Oncology (2024)
EP.12D.03 Characterization of HER2Alterations in 23,321 NSCLC Cases and Real-World Therapeutic Pattern in Chinese HER2-Mutant NSCLC the CHAPTER Study
Authors: B. Jia, J. Zhao, Z. Wang, T. An, Y. Wang, M. Zhuo, J. Li, X. Yang, H. Chen, Y. Chi, J. Wang, X. Zhai, R. Nuersulitan, X. Wang, Y. Tai, Y. Liu, G. Guan, Z. Dai, J. Song
Journal: Journal of Thoracic Oncology (2024)
EP.12A.14 Multicentered Real-World Evidence of Osimertinib Treatment in EGFR-Mutant Advanced Non-Small Cell Lung Cancer (NSCLC) In Thailand
Authors: T. Thamrongjirapat, P. Sitthideatphaiboon, S. Oranratnachai, K. Khiewngam, K. Maneenil, N. Prasongsook, K. Korphaisarn, S. Wangsubtawee, A. Rattanaphom, T. Reungwetwattana, V. Sriuranpong
Journal: Journal of Thoracic Oncology (2024)
EP.12A.11 Effect of Antibiotic Exposure on the Efficacy of EGFR TKIs in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
Authors: B. Pengnoraphat, S. Saichaemchan, T. Thambamroong, J. Phavirunsiri, K. Peechatanan, N. Prasongsook
Journal: Journal of Thoracic Oncology (2024)
EP.12B.08 Characterizing the Severity and Timing of Real-World ALK-Inhibitor Associated Weight Gain in Non-Small Cell Lung Cancer
Authors: A.S. Watson, J.M. Taormina, B. Yoder, S.J. Iwamoto, T. Patil, E.L. Schenk, D.R. Camidge
Journal: Journal of Thoracic Oncology (2024)
EP.04A.11 Patients Reported Outcomes in Short- And Long-Term Lung Cancer Survivors Who Were Diagnosed via Chest Low-Dose CT Screening
Authors: Y. Peng, D.E. Midthun, D. Liu, J.A. Wampfler, Z. Liu, J.L. Ridgeway, K. Tan, C.M. Wheatley-Guy, R.P. Benzo, M.R. Buras, N.Y. Yu, V. Ernani, J. D’Cunha, K.L. Swanson, Z. Gu, A. Jatoi, A.L. Cheville, P. Yang
Journal: Journal of Thoracic Oncology (2024)
EP.07B.02 Comparative Outcomes of Surgery and SBRT for Stage I Lung Cancer in Koreans: A Propensity Matched Multidisciplinary Cohort Study
Authors: E. Lee, Y.J. Suh, J.W. Park, S.H. Kwak, H.E. Kim, C.Y. Lee, J. Cho, E.Y. Kim
Journal: Journal of Thoracic Oncology (2024)
EP.04F.01 Challenges in Recruiting for a Randomized Controlled Intervention to Increase Lung Cancer Screening
Authors: L. Rios, D.T. Cooke, N. Hicks, S.L. Stewart, J.H. Dang, H. Leisy, S. MacDonald, C. Shulkin, R. Luna, J.E. Kohler, A. Elder, G. Salter, N. Singh, E.K. Tong, E.W. Chak, M. Chen, K. McHenry
Journal: Journal of Thoracic Oncology (2024)
EP.07A.19 Impact of Preoperative Pulmonary Function on Survival Following Lobectomy for Stage I and II Lung Cancer
Authors: K. Grapatsas, F. Doerr, F. Oezkan, N. Baldes, K. Darwiche, D. Theegarten, W. Eberhardt, T. Gauler, M. Stuschke, H. Hautzel, K. Herrmann, C. Taube, M. Forsting, M. Schuler, S. Bölükbas
Journal: Journal of Thoracic Oncology (2024)
EP.11A.19 Efficacy and Outcomes of Immunotherapy-Based Treatments in EGFR-Mutant Non-Small Cell Lung Cancer
Authors: I.-T. Chen, H.-C. Huang, C.-L. Chiang, C.-I. Shen, Y.-H. Tseng, Y.-M. Chen, Y.-H. Luo
Journal: Journal of Thoracic Oncology (2024)
EP.08D.14 Long-Term Prognosis of Patients Undergoing Trimodality Therapy for Locally Advanced Non-Small-Cell Lung Cancer
Authors: K. Okada, K. Suzawa, T. Ryuko, Y. Tomioka, S. Tanaka, K. Shien, K. Miyoshi, M. Okazaki, S. Sugimoto, E. Suzuki, J. Soh, S. Toyooka
Journal: Journal of Thoracic Oncology (2024)
EP.09B.05 The Role of Pulmonary Metastasectomy (PM) For Non-Primary Lung Cancer: Umbrella Review of Meta-Analyses
Authors: W. Woo, B. Park, A. Ahadi, L.I-y. Chung, C.M. Jung, A. Bharat, Y.K. Chae
Journal: Journal of Thoracic Oncology (2024)
EP.12A.02 What is the Optimal First-Line Regimen for EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Network Meta-Analysis
Authors: W. Zhang, Z. Guo, L. Ye, Z. Chen, K. Xu, X. Liu, Y. Liu, H. Wang, L. Zhao, W. Zhao, Y. He
Journal: Journal of Thoracic Oncology (2024)
EP.07D.10 Deciphering Destiny: Is Curation of NSCLC Limited to Stage IA?
Authors: F. Doerr, G. Grapatsas, N. Baldes, F. Oezkan, D. Theegarten, K. Darwiche, W.E.E. Eberhardt, M. Stuschke, H. Hautzel, K. Herrmann, C. Taube, M. Forsting, M. Schuler, S. Bölükbas
Journal: Journal of Thoracic Oncology (2024)
EP.03B.03 Whole Genome Analysis in Resected Adenocarcinoma and Squamous Cell Carcinoma of the Lungs
Authors: M. Ito, K. Suda, K. Sakai, S. Ohara, A. Hamada, M. Chiba, M. Shimoji, T. Takemoto, J. Soh, K. Nishio, T. Mitsudomi, Y. Tsutani
Journal: Journal of Thoracic Oncology (2024)
EP.04A.02 Automated Reading May Improve the Safety of Triennial Lung Cancer Screening Intervals for Low-Risk Subjects
Authors: R.E. Ledda, M. Balbi, F. Sabia, M. Ruggirello, R. Vigorito, G. Milanese, A. Marchianò, U. Pastorino
Journal: Journal of Thoracic Oncology (2024)
EP.12A.45 Study of the Mutational Profile of EGFR-Mutated Lung Cancer in the Russian Population on the Example of the City of Moscow
Authors: I. Kanner, A. Danilova, D. Stroyakovsky, N. Savelov, I. Demidova, Y. Akhmadiyarova, D. Sekhniaidze, M. Agasiev, N. Lapkin, D. Kanner
Journal: Journal of Thoracic Oncology (2024)
EP.06F.09 Epidemiological Profile of Patients with Non-Small Cell Lung Cancer Treated at Oncologia D' or Bahia from January 2018 to December 2022
Authors: M.D. Loula, M.I.d.S. Cesar, C.S.d.R. Baldotto, E. Mascarenhas
Journal: Journal of Thoracic Oncology (2024)
EP.06B.12 A Knowledge-Based Database on 1100 Non-Small Cell Lung Cancer from Italian Clinical Experience: The Biomarkers ATLAS
Authors: U. Malapelle, F. Passiglia, F. Pepe, P. Pisapia, M.L. Reale, D.L. Cortinovis, F. Fragetta, D. Galetta, E. Garbo, P. Graziano, F. Pagni, G. Pasello, P. Piovano, S. Pilotto, M. Tiseo, C. Genova, L. Righi, G. Troncone, S. Novello
Journal: Journal of Thoracic Oncology (2024)
Tumor-intrinsic role of ICAM-1 in driving metastatic progression of triple-negative breast cancer through direct interaction with EGFR
Authors: Jae-Hyeok Kang, Nizam Uddin, Seungmo Kim, Yi Zhao, Ki-Chun Yoo, Min-Jung Kim, Sung-Ah Hong, Sangsu Bae, Jeong-Yeon Lee, Incheol Shin, Young Woo Jin, Heather M. O’Hagan, Joo Mi Yi, Su-Jae Lee
Journal: Molecular Cancer (2024)

Triple-negative breast cancer (TNBC), the most aggressive subtype, presents a critical challenge due to the absence of approved targeted therapies. Hence, there is an urgent need to identify effective therapeutic targets for this condition. While epidermal growth factor receptor (EGFR) is prominently expressed in TNBC and recognized as a therapeutic target, anti-EGFR therapies have yet to gain approval for breast cancer treatment due to their associated side effects and limited efficacy. Here, we discovered that intercellular adhesion molecule-1 (ICAM-1) exhibits elevated expression levels in metastatic breast cancer and serves as a pivotal binding adaptor for EGFR activation, playing a crucial role in malignant progression. The activation of EGFR by tumor-expressed ICAM-1 initiates biased signaling within the JAK1/STAT3 pathway, consequently driving epithelial-to-mesenchymal transition and facilitating heightened metastasis without influencing tumor growth. Remarkably, ICAM-1-neutralizing antibody treatment significantly suppressed cancer metastasis in a breast cancer orthotopic xenograft mouse model. In conclusion, our identification of ICAM-1 as a novel tumor intrinsic regulator of EGFR activation offers valuable insights for the development of TNBC-specific anti-EGFR therapies.
EP.13D.06 Factors Affecting Outcomes of Limited-Stage I, IIA (T1-T2, N0, M0) Small Cell Lung Cancer: An Analysis of the National Cancer Database
Authors: H.M. Abdullah, A.C. Das, O.K. Abughanimeh, K.-L. Muir, B.B. Sharma, A.S. Marr, L.M. Smith, A.K. Ganti
Journal: Journal of Thoracic Oncology (2024)
EP.14C.06 Surgical and Local Treatment of Pain in Tietze Syndrome: Our Experience in University Hospital “Shefqet Ndroqi” Tirana Albania
Authors: F. Gradica, L. Lisha, A. Cani, D. Argjiri, F. Kokici, E. Dilko, I. Peposhi, R. Muhameti, K. Gradica, S. Bytyci
Journal: Journal of Thoracic Oncology (2024)
EP.13C.02 High-Dose Radiation Therapy for Limited-Stage Small-Cell Lung Cancer: Real-World Experience from Two Tertiary Centers
Authors: O. Icht, B. Krayim, M. Moskovitz, D. Reinhorn, O. Rotem, I. Averbuch, N. Peled, A. Allen
Journal: Journal of Thoracic Oncology (2024)
EP.12B.05 Drivers of Treatment Choice in ALK-Positive Metastatic Non-Small Cell Lung Cancer from Patients' and Caregivers' Perspectives
Authors: C. Danes, W. Wan, J. Seo, M. Trapali, H. Clarke, J.A. Whitty, K.W. Culver
Journal: Journal of Thoracic Oncology (2024)
P4.17F.05 Adherence to Clinical Practice Guideline - Analysis of 89 Multidisciplinary Team Discussed Patients with Stage III Lung Cancer
Authors: J.-T. Zhang, Y.-C. Zhang, W.-Z. Zhong, B.-C. Yin, G.-W. Che, M. Li, Y.-L. Wu, P.J.-Y. Cui
Journal: Journal of Thoracic Oncology (2024)
EP.07B.08 The Treatment Outcome of SBRT and Sublobar Resection for Vulnerable Elderly Patients with Stage IA Non-Small Cell Lung Cancer
Authors: M. Asami, S. Katsumata, K. Yasui, D. Yamaguchi, K. Matsushima, T. Masuda, K. Hayasaka, H. Kojima, H. Konno, M. Isaka, H. Harada, Y. Ohde
Journal: Journal of Thoracic Oncology (2024)
EP.12G.01 PFS as a Surrogate Endpoint for OS in Real-World Patients with ROS1+ advNSCLC in the United States
Authors: X. Ma, Y. Lu, A. Lee, C. Cho-Phan, I.-H. Su, Y. Zhang, R. Camidge, J.R. Penrod, Y. Yuan
Journal: Journal of Thoracic Oncology (2024)
EP.15B.03 Pilot Web-Based Study of Functional Status and Quality of Life Benefits Associated with Darbepoetin Alfa Use in Anemic Patients with Lung Cancer
Authors: I. Riano, M.A. Carey, H. Pomares-Millan, J. Moran, J.R. Rigas, K.H. Dragnev
Journal: Journal of Thoracic Oncology (2024)
EP.14C.03 Long-Term Outcomes of Unresectable Tracheobronchial Tumors Treated with Radiotherapy- Analysis from a Tertiary Cancer Centre
Authors: S. Dhingra, A. Tibdewal, J.P. Agarwal, S. Jiwnani, R. Kaushal, K. Prabhash
Journal: Journal of Thoracic Oncology (2024)
Cross‐Linker Architectures Impact Viscoelasticity in Dynamic Covalent Hydrogels
Authors: Yung‐Hao Lin, Junzhe Lou, Yan Xia, Ovijit Chaudhuri
Journal: Advanced Healthcare Materials (2024)

Abstract Dynamic covalent cross‐linked (DCC) hydrogels represent a significant advance in biomaterials for regenerative medicine and mechanobiology, offering viscoelasticity, and self‐healing properties that more closely mimic in vivo tissue mechanics than traditional, predominantly elastic, covalent hydrogels. However, the effects of varying cross‐linker architecture on DCC hydrogel viscoelasticity have not been thoroughly investigated. This study introduces hydrazone‐based alginate hydrogels to explore how cross‐linker architectures impact stiffness and viscoelasticity. In hydrogels with side‐chain cross‐linker (SCX), higher cross‐linker concentrations enhance stiffness and decelerate stress relaxation, while an off‐stoichiometric hydrazine‐to‐aldehyde ratio reduces stiffness and shortens relaxation time. In hydrogels with telechelic cross‐linking, maximal stiffness and relaxation time occurs at intermediate cross‐linker mixing ratio for both linear cross‐linker (LX) and star cross‐linker (SX), with higher cross‐linker valency further enhancing these properties. Further, the ranges of stiffness and viscoelasticity accessible with the different cross‐linker architectures are found to be distinct, with SCX hydrogels leading to slower stress relaxation relative to the other architectures, and SX hydrogels providing increased stiffness and slower stress relaxation versus LX hydrogels. This research underscores the pivotal role of cross‐linker architecture in defining hydrogel stiffness and viscoelasticity, providing insights for designing DCC hydrogels with tailored mechanical properties for specific biomedical applications.
EP.12A.31 Clinical Characteristics and Outcomes of EGFR-Positive Non-Small Cell Lung Cancer with Acquired RET Fusions
Authors: T. Kobayashi, Y. Shinno, Y. Yamaguchi, Y. Matsumoto, Y. Okuma, T. Yoshida, Y. Goto, H. Horinouchi, N. Yamamoto, Y. Ohe
Journal: Journal of Thoracic Oncology (2024)
EP.06B.10 Clinical Feasibility of Multiplex Digital PCR for Major Mutation Detection in NSCLC Patients: The Droplex NSCLC Panel Test
Authors: K.A. Kim, J.H. Ko, H.J. Youn, Y-j. Choe, M.R. Kang, H.S. Shim
Journal: Journal of Thoracic Oncology (2024)
EP.07A.12 Association Between Preoperative Diaphragm Thickness and Postoperative Complications in Elderly Patients with Lung Cancer
Authors: S. Kuriyama, K. Imai, S. Takashima, H. Iwai, H. Suzuki, R. Demura, Y. Harata, S. Shibano, Y. Minamiya
Journal: Journal of Thoracic Oncology (2024)
EP.07F.07 Role of Microbiome in the Outcome of the Preinvasive Lung Cancer Lesions
Authors: l. alqahtani, S. Ragavan, S. Rofael, A. Alhindi, Z. Whiteman, H. Harshad Pattani, R. Alkaraki, T. Alsabhan, M. Rabii, F. Koutentaki, G. Hewamana, C. shan, S. Gomez Lopez, A. Pennycuick, P. Durrenberger, L. Kalinke, M. Altammami, T.D. McHugh, S. Janes, V.H. Teixeira
Journal: Journal of Thoracic Oncology (2024)
EP.07A.05 Evolution of Use of Sublobar Resection in a US Population-Based Cohort Before and after Two Randomized Controlled Trials
Authors: O. Akinbobola, S. Ely, M.A. Ray, C. Fehnel, A. Saulsberry, K. Dortch, A. Minhas, T. Ng, J. Zhao, M.P. Smeltzer, R.U. Osarogiagbon
Journal: Journal of Thoracic Oncology (2024)
EP.06F.05 External Quality Assessment Results of Third-party NGS Laboratories in China for the Detection of Rare Mutations in Lung Cancer
Authors: Q. Yao, X. Zhou, L. Zhang, W. Fang, J. Ma, Q. Ye, C. Wu, Y. Hou, L. Dong, D. Su, Y. Tang, Z. Wang, H. Meng
Journal: Journal of Thoracic Oncology (2024)
EP.02G.01 Differentiation and Metabolic Phenotypes of Lung Squamous Cell Carcinoma Organoids are Modified by the Tumor Microenvironments
Authors: H. Ogawa, T. Koga, Y. Inoue, Y. Fujibayashi, R. Navab, Q. Li, N.-A. Pham, N. Radulovich, N. Bernards, Y. Sata, S. Kitazawa, Y. Hiraishi, F. Yokote, T. Aoi, Y. Maniwa, M.-S. Tsao, K. Yasufuku
Journal: Journal of Thoracic Oncology (2024)
EP.08D.01 Neoadjuvant Chemoimmunotherapy for Potentially Resectable IIIA/IIIB NSCLC(Neo-Pre-IC): Survival Updates and Predictive Effect of MRD
Authors: K. Ma, C. Sun, X. Wang, Y. Xu, G. Shao, Z. Yang, S. Qiu
Journal: Journal of Thoracic Oncology (2024)
EP.06B.05 Ultra-Stat Idylla EGFR Testing for Non-Small Cell Lung Carcinomas: Patient Selection and Impact on Clinical Outcomes
Authors: K.F. Fitzsimmons, C. Hughesman, M.-F. D'Amours, D. Alex, D.N. Ionescu, B. Melosky, K. McNeil, C. Ho, S. Yip, J. Naso
Journal: Journal of Thoracic Oncology (2024)
EP.11A.15 NSCLC-ClustOpt: A Semi-Supervised Optimized Clustering to Stratify Patients with NSCLC on Immune Checkpoint Blockers Therapy
Authors: F. Paoloni, F. Pecci, G. Bruschi, E. Tola, A. Sbrollini, T. Galassi, A. Borgheresi, V. Cognigni, L. Cantini, K.S. Saini, L. Santamaria, M. Gualtieri, V. Lunerti, M. Di Pietro Paolo, P. Mazzanti, V. Agostinelli, A. Agostini, G. Mentrasti, A. Giovagnoni, L. Burattini, R. Berardi
Journal: Journal of Thoracic Oncology (2024)
EP.05B.03 Evaluating the Risk of Pneumonitis from G-CSF in Thoracic Cancer Patients with Pre-Existing ILD
Authors: A. Komatsu, T. Mimori, M. Kuriyama, S. Fujioka, T. Miyawaki, T. Shukuya, K. Takahashi
Journal: Journal of Thoracic Oncology (2024)